METACLIPSE THERAPEUTICS CORP — Department of Health and Human Services SBIR Phase I: NIAID
METACLIPSE THERAPEUTICS CORP — SBIR Phase I award from Department of Health and Human Services.
Phase I SBIR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Health and Human Services in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $230,270. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Topic code NIAID links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $230,270
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- NIAID
- NAICS
- —
- Place of performance
- GA
- Period
- —
Description
The contractor will use engineered versions of IL and GM CSF as adjuvants The engineered version of IL and GM CSF include a glycosyl phosphatidylinositol GPI anchor at the carboxyl terminal which permits their incorporation into lipid bilayers such as influenza viral like particles VLP The development of the adjuvant will be in the context of influenza in elderly populations The specific tasks include the in vitro and in vivo establishment of an immunological profile of activity to evaluate the capability of the adjuvant